Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party.
Schuurhuis GJ, Heuser M, Freeman S, Béné MC, Buccisano F, Cloos J, Grimwade D, Haferlach T, Hills RK, Hourigan CS, Jorgensen JL, Kern W, Lacombe F, Maurillo L, Preudhomme C, van der Reijden BA, Thiede C, Venditti A, Vyas P, Wood BL, Walter RB, Döhner K, Roboz GJ, Ossenkoppele GJ. Schuurhuis GJ, et al. Among authors: cloos j. Blood. 2018 Mar 22;131(12):1275-1291. doi: 10.1182/blood-2017-09-801498. Epub 2018 Jan 12. Blood. 2018. PMID: 29330221 Free PMC article. Review.
Can we incorporate MRD assessment into clinical practice in AML?
Ossenkoppele G, Schuurhuis GJ, van de Loosdrecht A, Cloos J. Ossenkoppele G, et al. Among authors: cloos j. Best Pract Res Clin Haematol. 2019 Jun;32(2):186-191. doi: 10.1016/j.beha.2019.05.003. Epub 2019 May 10. Best Pract Res Clin Haematol. 2019. PMID: 31204000 Review.
Minimal residual disease and stem cell transplantation outcomes.
Cloos J, Ossenkoppele GJ, Dillon R. Cloos J, et al. Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):617-625. doi: 10.1182/hematology.2019000006. Hematology Am Soc Hematol Educ Program. 2019. PMID: 31808862 Free PMC article. Review.
MRD Tailored Therapy in AML: What We Have Learned So Far.
Ngai LL, Kelder A, Janssen JJWM, Ossenkoppele GJ, Cloos J. Ngai LL, et al. Among authors: cloos j. Front Oncol. 2021 Jan 15;10:603636. doi: 10.3389/fonc.2020.603636. eCollection 2020. Front Oncol. 2021. PMID: 33575214 Free PMC article. Review.
Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.
Ngai LL, Ma CY, Maguire O, Do AD, Robert A, Logan AC, Griffiths EA, Nemeth MJ, Green C, Pourmohamad T, van Kuijk BJ, Snel AN, Kwidama ZW, Venniker-Punt B, Cooper J, Manz MG, Gjertsen BT, Smit L, Ossenkoppele GJ, Janssen JJWM, Cloos J, Sumiyoshi T. Ngai LL, et al. Among authors: cloos j. Eur J Haematol. 2021 Sep;107(3):343-353. doi: 10.1111/ejh.13672. Epub 2021 Jun 26. Eur J Haematol. 2021. PMID: 34053123 Free PMC article.
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party.
Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, Tettero JM, Bachas C, Baer C, Béné MC, Bücklein V, Czyz A, Denys B, Dillon R, Feuring-Buske M, Guzman ML, Haferlach T, Han L, Herzig JK, Jorgensen JL, Kern W, Konopleva MY, Lacombe F, Libura M, Majchrzak A, Maurillo L, Ofran Y, Philippe J, Plesa A, Preudhomme C, Ravandi F, Roumier C, Subklewe M, Thol F, van de Loosdrecht AA, van der Reijden BA, Venditti A, Wierzbowska A, Valk PJM, Wood BL, Walter RB, Thiede C, Döhner K, Roboz GJ, Cloos J. Heuser M, et al. Among authors: cloos j. Blood. 2021 Dec 30;138(26):2753-2767. doi: 10.1182/blood.2021013626. Blood. 2021. PMID: 34724563 Free PMC article.
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party.
Tettero JM, Freeman S, Buecklein V, Venditti A, Maurillo L, Kern W, Walter RB, Wood BL, Roumier C, Philippé J, Denys B, Jorgensen JL, Bene MC, Lacombe F, Plesa A, Guzman ML, Wierzbowska A, Czyz A, Ngai LL, Schwarzer A, Bachas C, Cloos J, Subklewe M, Fuering-Buske M, Buccisano F. Tettero JM, et al. Among authors: cloos j. Hemasphere. 2021 Dec 22;6(1):e676. doi: 10.1097/HS9.0000000000000676. eCollection 2022 Jan. Hemasphere. 2021. PMID: 34964040 Free PMC article.
Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis.
Tettero JM, Al-Badri WKW, Ngai LL, Bachas C, Breems DA, van Elssen CHMJ, Fischer T, Gjertsen BT, van Gorkom GNY, Gradowska P, Greuter MJE, Griskevicius L, Juliusson G, Maertens J, Manz MG, Pabst T, Passweg J, Porkka K, Löwenberg B, Ossenkoppele GJ, Janssen JJWM, Cloos J. Tettero JM, et al. Among authors: cloos j. Front Oncol. 2022 Oct 10;12:999822. doi: 10.3389/fonc.2022.999822. eCollection 2022. Front Oncol. 2022. PMID: 36300090 Free PMC article.
205 results